Stanford Study Shows Pulsed Shortwave Therapy Provides Sustained Pain Relief for Thumb Arthritis
A Stanford University clinical trial demonstrates that pulsed shortwave therapy offers lasting pain relief for thumb arthritis, potentially providing a safe, drug-free alternative to current limited treatment options for millions of affected adults.
A double-blind, randomized controlled clinical trial conducted by Stanford University researchers has demonstrated that pulsed shortwave therapy provides sustained pain relief in adults with thumb carpometacarpal joint osteoarthritis, one of the most common and painful forms of hand arthritis. The study, involving 61 adults with clinically diagnosed thumb CMC osteoarthritis, compared outcomes between participants using an active PSWT device and those using an identical-appearing sham device over a four-week period.
Both groups wore their devices for approximately eight hours each night during the treatment phase. At the four-week mark, both groups reported meaningful reductions in pain, likely influenced by the splint-like stiffness of the devices and potential placebo effects. However, the critical finding emerged after device use was discontinued. By week six, only the PSWT group maintained its pain relief, while the sham group did not. The difference in pain reduction between PSWT and sham groups at this point was highly statistically significant with a p value of .02.
Other measures including maximum pain, hand function assessed through the Patient-Rated Wrist/Hand Evaluation (PRWHE), and single-assessment numeric evaluation (SANE) scores improved in both groups during the treatment period. The study abstract can be viewed at https://journals.sagepub.com/doi/10.1177/15589447251371088. The research suggests that PSWT may offer a true sustained analgesic benefit for thumb osteoarthritis that cannot be solely explained by splinting effects, placebo response, or continued device use.
PSWT was found to be safe and well tolerated throughout the study. Adverse events were infrequent and mild, most commonly minor skin irritation from the adhesive tape used with the devices. No serious adverse events occurred during the trial period. This safety profile is particularly important given that thumb arthritis affects an estimated 4-7 million U.S. adults with symptomatic thumb CMC arthritis, making everyday tasks like turning doorknobs, buttoning shirts, or opening jars difficult and painful.
The findings have significant implications for current treatment approaches to thumb arthritis, which are often limited to splints, medications, or injections. PSWT represents a potential safe, drug-free option that people can use at home, potentially changing how healthcare providers treat this widespread condition. BioElectronics Corporation, the developer of the technology, provides more information about their approach at https://www.bielcorp.com/. The study investigators concluded that PSWT may offer genuine sustained pain relief for one of the most challenging forms of hand arthritis affecting millions of adults.